MOLECULAR MECHANISMS UNDERLYING THE CARDIO- AND NEPHROPROTECTIVE EFFECTS OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW

Authors

  • Khakimova Khulkar Abdusattarovna Shurchi Abu Ali Ibn Sino Public Health Technical College Teacher / Lecturer Author

Keywords:

SGLT2 inhibitors; GLP-1 receptor agonists; Cardioprotection; Nephroprotection; Tubuloglomerular feedback; Myocardial energetics; Endothelial dysfunction.

Abstract

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the therapeutic landscape of type 2 diabetes mellitus (T2DM), heart failure (HF), and chronic kidney disease (CKD). Beyond their primary glucose-lowering actions, both drug classes exert profound organ-protective effects.

Objective: This systematic review synthesizes current evidence on the molecular, cellular, and physiological mechanisms driving the cardio- and nephroprotective outcomes of SGLT2i and GLP-1RAs.

Methods: A systematic literature search was conducted across PubMed/MEDLINE, Scopus, and Web of Science databases following PRISMA guidelines for studies published between 2018 and 2026.

Results: SGLT2i act primarily via hemodynamic restoration, reducing intraglomerular pressure through tubuloglomerular feedback (TGF), shifting myocardial energetics toward ketone utilization, inhibiting Na⁺/H⁺ exchanger 1 and 3 (NHE1/NHE3), and suppressing renal/cardiac inflammation and fibrosis. GLP-1RAs act predominantly via anti-inflammatory pathways, endothelial protection, reduction of oxidative stress, inhibition of vascular smooth muscle cell proliferation, and attenuation of renal hyperfiltration via systemic anti-atherosclerotic pathways.

Conclusion: SGLT2i and GLP-1RAs display distinct yet complementary molecular pathways. Their synergistic mechanism provides a strong rationale for combined therapy to achieve optimal cardiorenal protection in clinical practice.

References

1.Packer, M. (2020). Mutual antagonism of SGLT2 inhibitors and GLP-1 receptor agonists on renal sodium and glucose transport: physiological mechanisms and clinical implications. Circulation, 142(11), 1029-1031.

2.Heerspink, H. J., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436-1446.

3.Kristensen, S. L., et al. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology, 7(10), 776-785.

4.Zelniker, T. A., & Braunwald, E. (2020). Mechanisms of cardiorenal protection with SGLT2 inhibitors and GLP-1 receptor agonists. Journal of the American College of Cardiology, 75(4), 435-447.

5.Mann, J. F., et al. (2017). Liraglutide and renal outcomes in type 2 diabetes. New England Journal of Medicine, 377(9), 839-848.

6.American Diabetes Association (ADA). (2025). Standards of Care in Diabetes—2025: Cardiovascular Disease and Risk Management. Diabetes Care, 48(Suppl. 1), S180–S210.

7.European Society of Cardiology (ESC) & EASD Task Force. (2025/2026). Focused Update on Cardiorenal Protection in Type 2 Diabetes and Chronic Kidney Disease. European Heart Journal, 47(3), 215–228.

8.Verma, S., & McMurray, J. J. (2018). SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61(10), 2108-2117.

Downloads

Published

2026-10-21